Similar articles

• Oral cladribine and fingolimod for relapsing multiple sclerosis.

  Mann H. Mann H. N Engl J Med. 2010 May 6;362(18):1738; author reply 1739-40. doi: 10.1056/NEJMc1002550. N Engl J Med. 2010. PMID: 20445188 No abstract available.
• A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

  Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Clinical Trial.
• Oral therapy for multiple sclerosis--sea change or incremental step?

  Carroll WM. Carroll WM. N Engl J Med. 2010 Feb 4;362(5):456-8. doi: 10.1056/NEJMe0912019. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089958 No abstract available.
• Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.

  Sipe JC. Sipe JC. Expert Rev Neurother. 2010 Mar;10(3):365-75. doi: 10.1586/ern.10.12. Expert Rev Neurother. 2010. PMID: 20187859 Review.
• Cladribine: mode of action and implications for treatment of multiple sclerosis.

  Leist TP, Weissert R. Leist TP, et al. Clin Neuropharmacol. 2011 Jan-Feb;34(1):28-35. doi: 10.1097/WNF.0b013e318204cd90. Clin Neuropharmacol. 2011. PMID: 21242742 Review.